Abstract
The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation of both direct pro-fibrotic pathways and matrix metalloproteinases (MMPs) that enhance collagenase activity. Reactive fibrosis, i.e. deposition of ECM materials remote from the region of the MI is clearly detrimental to ventricular function and contributory to adverse outcomes post- MI. Therefore, reversal of this process represents an important therapeutic target in post-MI management and treatment of established heart failure. A number of existing agents exert their beneficial effects in part via reductions in ECM deposition. Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression.
Keywords: fibrosis, remodelling, renin-angiotensin, endothelin, transforming growth factor, collagen
Current Pharmaceutical Design
Title: Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Volume: 11 Issue: 4
Author(s): Fiona See, Andrew Kompa, Jennifer Martin, Dion A. Lewis and Henry Krum
Affiliation:
Keywords: fibrosis, remodelling, renin-angiotensin, endothelin, transforming growth factor, collagen
Abstract: The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation of both direct pro-fibrotic pathways and matrix metalloproteinases (MMPs) that enhance collagenase activity. Reactive fibrosis, i.e. deposition of ECM materials remote from the region of the MI is clearly detrimental to ventricular function and contributory to adverse outcomes post- MI. Therefore, reversal of this process represents an important therapeutic target in post-MI management and treatment of established heart failure. A number of existing agents exert their beneficial effects in part via reductions in ECM deposition. Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression.
Export Options
About this article
Cite this article as:
See Fiona, Kompa Andrew, Martin Jennifer, Lewis A. Dion and Krum Henry, Fibrosis as a Therapeutic Target Post-Myocardial Infarction, Current Pharmaceutical Design 2005; 11 (4) . https://dx.doi.org/10.2174/1381612053382098
DOI https://dx.doi.org/10.2174/1381612053382098 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Apoptotic Cell Clearance and Autoimmune Disorder
Current Medicinal Chemistry Mechanisms of Fetal and Neonatal Renal Impairment by Pharmacologic Inhibition of Angiotensin
Current Medicinal Chemistry Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Platelet Activation, Inflammatory Mediators and Hypercholesterolemia
Current Vascular Pharmacology Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry The Potential of Flavonolignans in Prostate Cancer Management
Current Medicinal Chemistry Angiotensin Converting Enzyme Inhibitor in Coronary Artery Bypass Surgery
Drug Design Reviews - Online (Discontinued) Potential Role of Hydrogen Sulfide in the Pathogenesis of Vascular Dysfunction in Septic Shock
Current Vascular Pharmacology Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Ghrelin in Obesity, Physiological and Pharmacological Considerations
Mini-Reviews in Medicinal Chemistry Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Melanocortin-4 Receptor Antagonists as Potential Therapeutics in the Treatment of Cachexia
Current Topics in Medicinal Chemistry All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Decade of Targets and Patented Drugs for Chemotherapy of Chagas Disease
Recent Patents on Anti-Infective Drug Discovery